Physician profile
Timothy Wuu
NPI 1750844122
$4,051.89
in general payments reported to CMS, 2019-2025
24 companies · $1,539 in 2025
The $1,539 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $320 · 2023: $851 · 2024: $1,342 · 2025: $1,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,732.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $609.25 | 2025 | Airsupra, Breztri, Farxiga |
| Becton, Dickinson and Company | $468.65 | 2022-2024 | Phasix Mesh |
| Lilly USA, LLC | $327.50 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $317.65 | 2023-2025 | Cologuard Collection Kit |
| Davol INC. | $301.15 | 2024-2025 | Channel Drain, Phasix Mesh |
| Glaxosmithkline, LLC. | $282.26 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boston Scientific Corporation | $276.49 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $208.62 | 2023-2025 | |
| Medtronic, INC. | $175.01 | 2022-2024 | Vanta Adaptivestim, Closurefast |
| Novo Nordisk INC | $152.95 | 2022-2025 | Ozempic, Rybelsus |
| Vertos Medical, INC. | $149.19 | 2024 | Mild Device Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.99 | 2024-2025 | Jardiance |
| Abbvie INC. | $135.32 | 2023-2025 | Viberzi |
| Amgen INC. | $133.14 | 2023-2025 | Tezspire, Repatha |
| Pfizer INC. | $118.15 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $45.14 | 2023 | |
| Phathom Pharmaceuticals, INC. | $44.97 | 2024-2025 | Voquezna |
| Currax Pharmaceuticals LLC | $42.11 | 2025 | Contrave |
| Globus Medical, INC. | $29.24 | 2025 | Senza |
| Dexcom, INC. | $23.55 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $16.36 | 2025 | Capvaxive, Gardasil 9 |
| Ibsa Pharma INC. | $16.25 | 2025 | Licart, Tirosint, Flector |
| Dynavax Technologies Corporation | $15.47 | 2025 | Heplisav-B |
| Shield Therapeutics INC | $14.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Wuu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.